I Dewa Made Widi Hersana and Siprianus Ugroseno Yudho Bintoro and Ami Ashariati Prayoga and Made Putra Sedana (2019) Correlation between Hasford Score with Early Molecular Response in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib. Biomedical & Pharmacology Journal, 12 (1). pp. 227-232. ISSN 1820-0254

	Text (Artikel) Correlation between Hasford score with early molecular response in patients with chronic myeloid leukemia in chronic phase treated with imatinib.pdf Download (331kB)
	Text (Peer Review) Correlation between Hasford.pdf Download (1MB)
	Text (Similarity) Correlation between hasford score with early molecular response in patients with chronic myeloid leukemia in chronic phase treated with imatinib.pdf Download (1MB)

Abstract

The aim of the study is to to determine correlation Hasford score and early molecular response in chronic phase BCR-ABL-Positive CML patients treated with imatinib. This is an longitudinal observational study in newly diagnosed patients of CML chronic phase BCR-ABL-Positive treated imatinib from Januari 2017 to September 2017. Patients were stratified according to Hasford score at diagnosis. Q-PCR(Quantitative RT-PCR) were used to monitor BCR-ABL transcription levels after 3 months of imatinib treatment. Correlation between Hasford score with early molecular response were analyzed using Koefisien Kontingensi’s correlation test. Results: Thirty five patients were enrolled in this study consist of 13 male and 22 female. After 3 months of imatinib treatment, EMR were 5 patients (83.3%), 11 patients (61.1%) and 2 patients (18.2%) in low, intermediate, and high risk group patients, respectively. Koefisien kontigensi test showed that there was significant correlation between Hasford score and EMR (p=0.018; r=0.431). The Hasford score correlated to early molecular response in chronic phase BCR-ABL-positive CML patients received imatinib.

Actions (login required)

View Item